Dr Agarwal’s Healthcare IPO Listing: The equity shares of Dr Agarwal’s Health Care Ltd are set to be listed on stock exchanges tomorrow, February 4, after a lukewarm response to its initial ...

Following the three days of bidding, Dr. Agarwal's Health Care IPO closed with strong demand, garnering 1.49 times bids. The IPO received bids for 7.98 crore shares against 5.35 crore shares on offer.

Bhavish Aggarwal holds nearly a 9% stake in Ola Consumer, 36% in the now publicly listed Ola Electric, and around 90% in Ola Krutrim Ola founder Bhavish Aggarwal is planning to restructure his ...

India's palm oil imports in January plunged to their lowest level in nearly 14 years as refiners replaced the tropical oil with cheaper rival soyoil because of negative refining margins for palm ...

Bhavish Aggarwal posted about the store expansion on X hours before informing BSE and NSE. Ola faces potential enforcement action if compliance standards aren't improved. This occurs amidst other ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

It is with deep sorrow that we announce the passing of Dr. Mukesh Aggarwal, a highly respected and dedicated ophthalmologist, on January 10, 2025. Dr. Aggarwal, beloved husband to Rajee Paul ...

Ola founder Bhavish Aggarwal has invested ₹2,000 crore in his artificial intelligence startup, Krutrim, with plans to increase the investment to ₹10,000 crore by next year. The company has ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

Ola founder Bhavish Aggarwal on February 4 announced an investment of Rs 2,000 crore into his artificial intelligence venture Krutrim, with a commitment of Rs 10,000 crore by next year ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...